Skip to content
Novo Nordisk Invests DKK 8.5bn in Danish Rare Disease Production Facility
Novo Nordisk’s DKK 8.5bn investment in Odense facility supports rare disease treatments and sustainability.
Novo Nordisk’s DKK 8.5bn investment in Odense facility supports rare disease treatments and sustainability.